Related Experiment Video
Updated: Jan 8, 2026

Calcification of Vascular Smooth Muscle Cells and Imaging of Aortic Calcification and Inflammation
Published on: May 31, 2016
DDR1 Regulates Femoral Arterial Calcification in Lower-Extremity Artery Disease Through NF-Kappa B Activation
Manovriti Thakur1,2, Thibaut Quillard3, Nico Angliker1,2
1Division of Angiology, Swiss Cardiovascular Center, Inselspital, Bern University Hospital, University of Bern, Bern, Switzerland.
Insights
This study identifies DDR1 as a key driver of medial arterial calcification (MAC) in lower-extremity arterial disease (LEAD). Targeting DDR1 may offer a novel therapeutic approach to prevent MAC in LEAD patients.
Area of Science:
- Vascular Biology
- Cardiovascular Disease Research
- Molecular Medicine
Background:
- Lower-extremity arterial disease (LEAD) affects 230 million globally, with medial arterial calcification (MAC) common in patients and linked to mortality.
- Current therapeutic strategies for femoral MAC in LEAD are lacking, and its underlying mechanisms require elucidation.
- Understanding the molecular drivers of femoral MAC is crucial for developing targeted treatments.
Purpose of the Study:
- To identify molecular drivers of femoral medial arterial calcification (MAC) in patients with lower-extremity arterial disease (LEAD).
Main Methods:
- Analysis of human patient samples using von Kossa staining, immunofluorescence, and gene expression.
- Assessment of medial calcification in Apoe-/- mice fed a Western diet (WD).
- In vitro experiments with murine and human vascular smooth muscle cells (VSMCs) to evaluate DDR1's role in calcification.
Main Results:
- Femoral arteries showed significantly higher calcification and pro-calcifying gene expression (DDR1, BMP2) compared to carotids.
- DDR1 expression positively correlated with calcification in human femoral samples.
- DDR1 inhibition reduced, while activation increased, calcium deposition in VSMCs; DDR1 stimulation activated NF-κB, a pathway implicated in calcification.
Conclusions:
- DDR1 is identified as a key molecular driver of calcification in LEAD, operating via NF-κB activation.
- Targeting DDR1 presents a potential novel therapeutic strategy for preventing medial arterial calcification in LEAD.
- Further research into DDR1 inhibition could lead to new treatments for atherosclerotic cardiovascular disease manifestations.
Aim:
Lower-extremity arterial disease (LEAD) is a manifestation of atherosclerotic cardiovascular disease, affecting 230 million people worldwide with increasing prevalence. Medial arterial calcification (MAC) is common in LEAD patients and contributes to disease-related mortality. However, therapeutic strategies targeting femoral MAC are lacking, and its underlying mechanisms remain unclear. This study aimed to identify molecular drivers of femoral MAC in LEAD.
Methods & Results:
Calcium deposits and pro-calcifying markers were analyzed in human patient samples using von Kossa staining, immunofluorescence, and gene expression analysis. Femorals showed significantly more calcification and pro-calcifying gene expression than carotids. Given MAC abundance in LEAD, we assessed medial calcification in Apoe-/- mice fed a WD for 4/21 weeks. Digital PCR revealed upregulation of Ddr1 and Bmp2 in femoral versus carotid arteries after 21 weeks of WD. DDR1 expression positively correlated with calcification in human femoral samples. In vitro experiments with mouse femoral vs. carotid vascular smooth muscle cells (VSMCs) confirmed a significantly higher prevalence of calcifying proteins (DDR1, BMP2, and RUNX2) in femoral VSMCs. Additionally, calcification analyses in murine and human VSMCs showed that DDR1 inhibition reduced, while DDR1 activation increased, calcium deposition. Transcriptomic analysis revealed elevated NF-κB expression in human femoral arteries, matching data in femoral VSMCs. DDR1 stimulation activated NF-κB, and its inhibition blocked DDR1-induced calcification.
Conclusion:
This study identifies DDR1 as a key driver of calcification in LEAD, operating through NF-κB activation and the expression of calcifying proteins. Targeting DDR1 may offer a novel therapeutic approach to prevent MAC in LEAD.
Related Concept Videos
Peripheral Artery Disease I: Introduction
NF-κB-dependent Signaling Pathway
NF-κB-dependent Signaling Mechanism
The...
Peripheral Arterial Disease II: Clinical Manifestations and Diagnostic Evaluation

